Overview
LL-37 is a peptide made of 37 amino acids and part of the body’s defenses against infection. Researchers study its antibacterial activity and role in wound healing.
LL-37 is not approved by the Food and Drug Administration for human use, and no prescription version exists. It should only be used within an approved clinical study and never taken without a doctor’s authorization.
What is it being studied for?
Research is focused on chronic wounds that will not close, particularly venous leg ulcers, and on bacterial infection.
LL-37 can damage bacterial membranes. It also affects signals involved in skin cell movement and blood vessel growth during wound repair.
What has research found?
A small placebo-controlled study found faster wound healing with lower concentrations of LL-37 applied to venous leg ulcers. A later trial involving 148 patients found no significant improvement in healing across the full study group.
Animal and laboratory studies have examined LL-37’s role in wound repair. It is also found in healing human skin wounds.
The human trials tested LL-37 applied to wounds, rather than injected.
FDA status and development history
LL-37 was identified in the 1990s. Human trials have examined topical wound treatments. It is not FDA-approved.